CXR Biosciences' Anti-Cancer Drug Development Programme

The recent exponential increase in the knowledge of tumour biology and genetics has heralded a new era of targeted oncology medicine.

CXR is appliying these insights to improve and rationalise anticancer drug discovery and development. The latest molecular and genetic technologies are used to determine the biological mechanisms involved in both efficacy and toxicity. This knowledge enables the selection of leads most likely to succeed in the clinic and optimises the design of the preclinical development plan to reduce development time, reduce costs, reduce late stage attrition, and improve the probability of clinical success.

 CXRBiosciences anticancer drug development programme is an integrated offering combining a comprehensive range of assays with a high level of oncology expertise provided by CXR Biosciences.

• Improved 'mechanism-based' ADMET lead selection studies more
• Improved Efficacy studies
• HRN™ nude mice, optimise bioavailability to increase the chance of demonstrating in vivo efficacy in xenograft models  more
• Identification of responder tumour types through mechanistic and cell-based assay more.
• Assessment of Combination therapeutics – “isobologram analysis” more
• Mechanisms of On/Off target effects
• Laser capture microdissection coupled with transcription profiling analysis of xenograft tumours to assess mechanism of action 
• Gene expression profiling and pathways analysis of normal tissues (liver, kidney etc) to predict potential adverse effects.  more